Vaginal rings with exposed cores for sustained delivery of the HIV CCR5 inhibitor 5P12-RANTES

被引:36
|
作者
McBride, John W. [1 ]
Boyd, Peter [1 ]
Dias, Nicola [2 ]
Cameron, David [2 ]
Offord, Robin E. [3 ]
Hartley, Oliver [3 ,4 ]
Kett, Vicky L. [1 ]
Malcolm, R. Karl [1 ]
机构
[1] Queens Univ Belfast, Sch Pharm, Belfast BT9 7BL, Antrim, North Ireland
[2] Envigo, Huntingdon, Cambs, England
[3] Mintaka Fdn Med Res, Geneva, Switzerland
[4] Univ Geneva, Fac Med, Dept Pathol & Immunol, Geneva, Switzerland
基金
英国惠康基金;
关键词
HIV microbicide; Sustained release; Silicone elastomer; Sheep pharmacokinetics; Protein drug delivery; INTRAVAGINAL RING; SILICONE ELASTOMER; CONTROLLED-RELEASE; POLYCAPROLACTONE MATRICES; CURE CHARACTERISTICS; DRUG RELEASE; PROTEIN; TENOFOVIR; SAFETY; PHARMACOKINETICS;
D O I
10.1016/j.jconrel.2019.02.003
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Antiretroviral-releasing vaginal rings are at the forefront of ongoing efforts to develop microbicide-based strategies for prevention of heterosexual transmission of the human immunodeficiency virus (HIV). However, traditional ring designs are generally only useful for vaginal administration of relatively potent, lipophilic, and small molecular weight drug molecules that have sufficient permeability in the non-biodegradable silicone elastomer or thermoplastic polymers. Here, we report a novel, easy-to-manufacture 'exposed-core' vaginal ring that provides sustained release of the protein microbicide candidate 5P12-RANTES, an experimental chemokine analogue that potently blocks the HIV CCR5 coreceptor. In vitro release, mechanical, and stability testing demonstrated the utility and practicality of this novel ring design. In a sheep pharmacokinetic model, a ring containing two 1/4 -length excipient-modified silicone elastomer cores - each containing lyophilised 5P12-RANTES and exposed to the external environment by two large windows - provided sustained concentrations of 5P12-RANTES in vaginal fluid and vaginal tissue between 10 and 10,000 ng/g over 28days, at least 50 and up to 50,000 times the reported in vitro IC50 value.
引用
收藏
页码:1 / 11
页数:11
相关论文
共 50 条
  • [21] The effects of RANTES/CCR5 promoter polymorphisms on HIV disease progression in HIV-infected Koreans
    Jang, D. H.
    Choi, B. -S.
    Kim, S. S.
    INTERNATIONAL JOURNAL OF IMMUNOGENETICS, 2008, 35 (02) : 101 - 105
  • [22] Multifaceted Mechanisms of HIV Inhibition and Resistance to CCR5 Inhibitors PSC-RANTES and Maraviroc
    Lobritz, Michael A.
    Ratcliff, Annette N.
    Marozsan, Andre J.
    Dudley, Dawn M.
    Tilton, John C.
    Arts, Eric J.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (06) : 2640 - 2650
  • [23] Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor
    Veazey, RS
    Springer, MS
    Marx, PA
    Dufour, J
    Klasse, PJ
    Moore, JP
    NATURE MEDICINE, 2005, 11 (12) : 1293 - 1294
  • [24] Pharmacokinetics of a CCR5 inhibitor in rhesus macaques following vaginal, rectal and oral application
    Malcolm, R. Karl
    Lowry, Deborah
    Boyd, Peter
    Geer, Leslie
    Veazey, Ronald S.
    Goldman, Laurie
    Klasse, P. J.
    Shattock, Robin J.
    Moore, John P.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (05) : 1325 - 1329
  • [25] Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor
    Ronald S Veazey
    Martin S Springer
    Preston A Marx
    Jason Dufour
    Per Johan Klasse
    John P Moore
    Nature Medicine, 2005, 11 : 1293 - 1294
  • [26] Chemokine receptor-5 (CCR5) is a receptor for the HIV entry inhibitor peptide T (DAPTA)
    Polianova, MT
    Ruscetti, FW
    Pert, CB
    Ruff, MR
    ANTIVIRAL RESEARCH, 2005, 67 (02) : 83 - 92
  • [27] CCR5 genotype and HIV-1 infection in perinatally-exposed infants
    Mas, A
    Español, T
    Heredia, A
    Pedraza, MA
    Hernandez, M
    Caragol, I
    Fernando, M
    Bertran, JM
    Alcami, J
    Soriano, V
    JOURNAL OF INFECTION, 1999, 38 (01) : 9 - 11
  • [28] Vicriviroc, A Novel CCR5 Inhibitor, is NOT A p-glycoprotein Substrate In Vitro
    Cheng Li
    Anther Keung
    Richard A Morrison
    Ronald E White
    Retrovirology, 2
  • [29] Vicriviroc, a novel CCR5 inhibitor, is not a p-glycoprotein substrate in vitro
    Li, Cheng
    Keung, Anther
    Morrison, Richard A.
    White, Ronald E.
    RETROVIROLOGY, 2005, 2 (Suppl 1)
  • [30] Structure of the CCR5 Chemokine Receptor-HIV Entry Inhibitor Maraviroc Complex
    Tan, Qiuxiang
    Zhu, Ya
    Li, Jian
    Chen, Zhuxi
    Han, Gye Won
    Kufareva, Irina
    Li, Tingting
    Ma, Limin
    Fenalti, Gustavo
    Li, Jing
    Zhang, Wenru
    Xie, Xin
    Yang, Huaiyu
    Jiang, Hualiang
    Cherezov, Vadim
    Liu, Hong
    Stevens, Raymond C.
    Zhao, Qiang
    Wu, Beili
    SCIENCE, 2013, 341 (6152) : 1387 - 1390